IMPORTANCE: Soy consumption has been suggested to reduce risk or recurrence of prostate cancer, but this has not been tested in a randomized trial with prostate cancer as the end point. OBJECTIVE: To determine whether daily consumption of a soy protein isolate supplement for 2 years reduces the rate of biochemical recurrence of prostate cancer after radical prostatectomy or delays such recurrence. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind trial conducted from July 1997 to May 2010 at 7 US centers comparingdaily consumption of a soy protein supplement vs placebo in 177 men at high risk of recurrence after radical prostatectomy for prostate cancer. Supplement intervention was started within 4 months after surgery and continued for up to 2 years, with prostate-specific antigen (PSA) measurements made at 2-month intervals in the first year and every 3 months thereafter. INTERVENTION: Participants were randomized to receive a daily serving of a beverage powder containing 20 g of protein in the form of either soy protein isolate (n=87) or, as placebo, calcium caseinate (n=90). MAIN OUTCOMES AND MEASURES: Biochemical recurrence rate of prostate cancer (defined as development of a PSA level of ≥0.07 ng/mL) over the first 2 years following randomization and time to recurrence. RESULTS: The trial was stopped early for lack of treatment effects at a planned interim analysis with 81 evaluable participants in the intervention group and 78 in the placebo group. Overall, 28.3% of participants developed biochemical recurrence within 2 years of entering the trial (close to the a priori predicted recurrence rate of 30%). Among these, 22 (27.2%) occurred in the intervention group and 23 (29.5%) in the placebo group. The resulting hazard ratio for active treatment was 0.96 (95% CI, 0.53-1.72; log-rank P = .89). Adherence was greater than 90% and there were no apparent adverse events related to supplementation. CONCLUSION AND RELEVANCE: Daily consumption of a beverage powder supplement containing soy protein isolate for 2 years following radical prostatectomy did not reduce biochemical recurrence of prostate cancer in men at high risk of PSA failure. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00765479.
RCT Entities:
IMPORTANCE: Soy consumption has been suggested to reduce risk or recurrence of prostate cancer, but this has not been tested in a randomized trial with prostate cancer as the end point. OBJECTIVE: To determine whether daily consumption of a soy protein isolate supplement for 2 years reduces the rate of biochemical recurrence of prostate cancer after radical prostatectomy or delays such recurrence. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind trial conducted from July 1997 to May 2010 at 7 US centers comparing daily consumption of a soy protein supplement vs placebo in 177 men at high risk of recurrence after radical prostatectomy for prostate cancer. Supplement intervention was started within 4 months after surgery and continued for up to 2 years, with prostate-specific antigen (PSA) measurements made at 2-month intervals in the first year and every 3 months thereafter. INTERVENTION: Participants were randomized to receive a daily serving of a beverage powder containing 20 g of protein in the form of either soy protein isolate (n=87) or, as placebo, calcium caseinate (n=90). MAIN OUTCOMES AND MEASURES: Biochemical recurrence rate of prostate cancer (defined as development of a PSA level of ≥0.07 ng/mL) over the first 2 years following randomization and time to recurrence. RESULTS: The trial was stopped early for lack of treatment effects at a planned interim analysis with 81 evaluable participants in the intervention group and 78 in the placebo group. Overall, 28.3% of participants developed biochemical recurrence within 2 years of entering the trial (close to the a priori predicted recurrence rate of 30%). Among these, 22 (27.2%) occurred in the intervention group and 23 (29.5%) in the placebo group. The resulting hazard ratio for active treatment was 0.96 (95% CI, 0.53-1.72; log-rank P = .89). Adherence was greater than 90% and there were no apparent adverse events related to supplementation. CONCLUSION AND RELEVANCE: Daily consumption of a beverage powder supplement containing soy protein isolate for 2 years following radical prostatectomy did not reduce biochemical recurrence of prostate cancer in men at high risk of PSA failure. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00765479.
Authors: Ralph W deVere White; Alexander Tsodikov; Eschelle C Stapp; Stephanie E Soares; Hajime Fujii; Robert M Hackman Journal: Nutr Cancer Date: 2010 Impact factor: 2.900
Authors: David J A Jenkins; Cyril W C Kendall; Mario A D'Costa; Chung-Ja Jackson; Edward Vidgen; William Singer; Jason A Silverman; George Koumbridis; John Honey; A Venket Rao; Neil Fleshner; Laurence Klotz Journal: J Urol Date: 2003-02 Impact factor: 7.450
Authors: Kenneth F Adams; Chu Chen; Katherine M Newton; John D Potter; Johanna W Lampe Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-04 Impact factor: 4.254
Authors: Jennifer H Ahn-Jarvis; Steven K Clinton; Elizabeth M Grainger; Kenneth M Riedl; Steven J Schwartz; Mei-Ling T Lee; Raul Cruz-Cano; Gregory S Young; Gregory B Lesinski; Yael Vodovotz Journal: Cancer Prev Res (Phila) Date: 2015-08-14
Authors: Gregory B Lesinski; Patrick K Reville; Thomas A Mace; Gregory S Young; Jennifer Ahn-Jarvis; Jennifer Thomas-Ahner; Yael Vodovotz; Zeenath Ameen; Elizabeth Grainger; Kenneth Riedl; Steven Schwartz; Steven K Clinton Journal: Cancer Prev Res (Phila) Date: 2015-08-14
Authors: Sam F Peisch; Erin L Van Blarigan; June M Chan; Meir J Stampfer; Stacey A Kenfield Journal: World J Urol Date: 2016-08-12 Impact factor: 4.226
Authors: Ali I Amjad; Rahul A Parikh; Leonard J Appleman; Eun-Ryeong Hahm; Kamayani Singh; Shivendra V Singh Journal: Curr Pharmacol Rep Date: 2015-04-16
Authors: Antonino Battaglia; Gaëtan Devos; Guy Boeckx; Lieven Goeman; Lorenzo Tosco; Gert de Meerleer; Steven Joniau Journal: Curr Urol Date: 2020-10-13